Kidney Cancer Market 2022-2028

Description

List of Tables

Global Kidney Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Renal Cell Carcinoma (RCC), Transitional Cell Cancer, Wilm's Tumor (Nephroblastoma), and Others (Sarcoma, Lymphoma)), by Cancer Cell (Clear Cell, Papillary, and Other) by Diagnosis (Biopsy, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), and Ultrasound) and by Therapy (Surgery, Immunotherapy, Chemotherapy, Radiation Therapy, and Cryotherapy) Forecast (2022-2028)

The global kidney cancer market is anticipated to grow at a substantial CAGR of 6.2% during the forecast period. As per the American Cancer Society, kidney cancer is among the 10 most common cancers in both men and women. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%). The lifetime risk for women is about 1 in 80 (1.03%). Reduced physical activity and excessive smoking and drinking are also a factor that is driving the kidney cancer market.

The global kidney cancer market is segmented based on the cancer type, cancer cell, diagnosis, and therapy. Based on the cancer type, the market is segmented into renal cell carcinoma (RCC), transitional cell cancer, Wilm's tumor (nephroblastoma), and others. Based on the cancer cell, the market is sub-segmented into a clear cell, papillary, and other. Based on the diagnosis, the market is sub-segmented into biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), and ultrasound. Based on therapy, the market is sub-segmented into surgery, immunotherapy, chemotherapy, radiation therapy, and cryotherapy.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The market in the Asia-Pacific region is growing during the forecast period. The major countries contributing to the APAC region are China, Australia, Japan, and India. A large customer base, high consumption of Tabaco, and continuous increment in economy and healthcare facility are the major factor for the growth of the market in the region. The drugmaker launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer, in India. The drug is launched at an MRP that is approximately 96% lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg), and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).

The major companies serving the global kidney cancer market include AbbVie Inc., Bayer Pharma AG, Merck & Co., GlaxoSmithKline Plc, and Pfizer Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2021, MSN Labs launched Cabolong, a branded generic of Cabozantinib, for the treatment of renal cell carcinoma. Cabolong is available in 20mg, 40mg, and 60mg strengths at the pricing of below ₹10,000 for a monthly treatment regimen with the highest strength.

Research Methodology

The market study of the global pharmaceutical filtration market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Kidney Cancer Market Research and Analysis by Cancer Type.

2. Global Kidney Cancer Market Research and Analysis by Cancer Cell.

3. Global Kidney Cancer Market Research and Analysis by Diagnosis.

4. Global Kidney Cancer Market Research and Analysis by Therapy.

The Report Covers:

Comprehensive Research Methodology of the global pharmaceutical filtration market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global pharmaceutical filtration market.
Insights about market determinants that are stimulating the global pharmaceutical filtration market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026497

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Kidney Cancer Market
Recovery Scenario of Global Kidney Cancer Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. Abbvie Inc.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Bayer Pharma AG
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Merck & Co.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Glaxosmithkline Plc
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Pfizer Inc.
- 3.6.1. Overview
- 3.6.2. Financial Analysis
- 3.6.3. SWOT Analysis
- 3.6.4. Recent Developments
3.7. Key Strategy Analysis
3.8. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. Global Kidney Cancer Market by Cancer Type
- 4.1.1. Renal Cell Carcinoma (RCC)
- 4.1.2. Transitional Cell Cancer
- 4.1.3. Wilm's Tumour (Nephroblastoma)
- 4.1.4. Others (Sarcoma, Lymphoma)
4.2. Global Kidney Cancer Market by Cancer Cell
- 4.2.1. Clear Cell
- 4.2.2. Papillary
- 4.2.3. Other
4.3. Global Kidney Cancer Market by Diagnosis Method
- 4.3.1. Biopsy
- 4.3.2. Computed Tomography (CT) scan
- 4.3.3. Magnetic Resonance imaging (MRI)
- 4.3.4. Ultrasound
4.4. Global Kidney Cancer Market by Therapy
- 4.4.1. Surgery
- 4.4.2. Immunotherapy
- 4.4.3. Chemotherapy
- 4.4.4. Radiation Therapy
- 4.4.5. Cryotherapy

5. Regional Analysis

5.1. North America
- 5.1.1. US
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profile

6.1. Active Biotech AB
6.2. Actuate Therapeutics, Inc.
6.3. Adaptimmune Therapeutics plc.
6.4. Amgen Inc.
6.5. Astrazeneca Plc
6.6. Cipla Inc.
6.7. Eisai Co., Ltd.
6.8. Exelixis, Inc.
6.9. F. Hoffmann-La Roche Ltd
6.10. Genentech, Inc.
6.11. Jazz Pharmaceuticals, Inc.
6.12. Novartis AG
6.13. Prometheus Laboratories.
6.14. Sanofi
6.15. Takeda Pharmaceutical Co. Ltd.